4D MOLECULAR THERAPEUTICS, INC. - Annual Financials - Income Statement (SEC)

Updated on January 2, 2026.

Related Topics: SEC Topic List.

Data Source: SEC.

See details in table below.

You can see similar for other companies.

4D MOLECULAR THERAPEUTICS, INC. - Annual Income Statement (In Thousands of USD, Except Per Share Amounts)

Breakdown	2024-12-31	2023-12-31
Collaboration and license revenue	37	20723
Research and development (includes $1,005 and $183 for the years ended December 31, 2024 and 2023, respectively, attributable to related parties)	141299	97096
General and administrative	46579	36494
Total operating expenses	187878	133590
Loss from operations	-187841	-112867
Interest income	27050	12211
Other expense, net	-77	-181
Total other income, net	26973	12030
Net loss	-160868	-100837
Basic Earnings Per Share	-2.98	-2.58
Diluted Earnings Per Share	-2.98	-2.58
Basic Weighted Average Shares Outstanding	53943.741	39130.067
Diluted Weighted Average Shares Outstanding	53943.741	39130.067
Research and development expense, related party	1005	183